ArticlePediatric surgery international2026
CT-guided methylene blue staining to facilitate thoracoscopic resection of intermediate-to-deep pulmonary metastases in pediatric patients.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThoracoscopic resection of pulmonary metastases offers a minimally-invasive approach but requires preoperative localization due to absent tactile feedback. CT-guided methylene blue staining (MBS) was implemented to facilitate resection of pulmonary metastases, including intermediate-to-deep lesions.
methodsWe retrospectively analyzed pediatric patients (0-18 years) undergoing resection of pulmonary metastases (2007-2024). Lesion depth was classified as superficial (≤ 10 mm), intermediate (11-20 mm), or deep (> 20 mm). Primary endpoint was completeness of resection; secondary endpoints included perioperative and oncological outcomes. Subgroup analysis included patients with ≤ 2 pulmonary metastases.
resultsFifty-eight resections in 43 patients were included: 49 open, and 9 thoracoscopic following CT-guided MBS. Eleven lesions were stained prior to thoracoscopic resection: three superficial, seven intermediate, one deep lesion. All were resected with negative margins, without complications. Thoracoscopy following CT-guided MBS was associated with shorter operative times (65 vs. 157 min, p = 0.01), hospital stay (4.0 vs. 5.6 days, p = 0.01), and time-to-chemotherapy-resumption (2.25 vs. 18.6 days, p = 0.01). No differences were observed in pulmonary recurrence, disease-free interval, or six-month-survival.
conclusionIn pediatric patients with up to two pulmonary metastases, CT-guided methylene blue staining provided feasible preoperative localization, facilitating thoracoscopic wedge resection of superficial, intermediate and deep lesions without complications. Prospective multicenter studies should further evaluate efficacy and inclusion criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.